Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
547.55
+0.26 (+0.05%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
76
77
Next >
3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April
↗
April 09, 2024
These high-growth biotech stocks are certainly worth considering for investors looking for market-beating returns in the long-term.
Via
InvestorPlace
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
↗
April 09, 2024
These companies are close to launching new products that could supercharge revenue.
Via
The Motley Fool
Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul
↗
April 05, 2024
These businesses are booming.
Via
The Motley Fool
Biotech Sector Nears Breakout: Will it Outperform in Q2?
April 03, 2024
The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains
Via
MarketBeat
Topics
ETFs
Missed the "Magnificent Seven"? Try Buying These 3 Forever Stocks Instead
↗
April 01, 2024
All three companies have very long runways for growth ahead.
Via
The Motley Fool
1 Top Growth Stock to Buy and Hold Forever
↗
March 31, 2024
This drugmaker looks unstoppable.
Via
The Motley Fool
If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,400 Today
↗
March 25, 2024
Via
Benzinga
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
April 01, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Meet The "Magnificent Seven" of Healthcare Stocks
↗
April 01, 2024
The tech sector doesn't have a monopoly on magnificent corporations.
Via
The Motley Fool
2 Rock-Solid Growth Stocks to Buy Right Now and Hold for at Least 5 Years
↗
March 31, 2024
Great businesses are here to stay. These are two excellent examples.
Via
The Motley Fool
3 Unstoppable Stocks to Buy Hand Over Fist in April
↗
March 30, 2024
These stocks have exceptionally bright prospects.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
↗
March 28, 2024
Via
Benzinga
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why
↗
March 28, 2024
The company is working to launch its Vertex-partnered gene-editing drug for sickle cell disease and beta thalassemia.
Via
Investor's Business Daily
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
↗
March 26, 2024
These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run.
Via
InvestorPlace
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
↗
March 25, 2024
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom.
Via
InvestorPlace
FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease”
March 25, 2024
Via
AB Newswire
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
March 21, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
3 Biopharma Stocks Predicted to Soar in Q2 2024
↗
March 20, 2024
These biopharma stocks can produce massive returns for Q2 based on new product releases and international treatment approvals.
Via
InvestorPlace
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
March 20, 2024
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel
Via
MarketBeat
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
↗
March 19, 2024
These biotech stocks to buy offer a gateway to long-term gains, on the back of groundbreaking healthcare innovations.
Via
InvestorPlace
2 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
↗
March 17, 2024
It's always a good time to buy great stocks with excellent prospects.
Via
The Motley Fool
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
↗
March 17, 2024
There's no need for delays in buying these great stocks.
Via
The Motley Fool
Forget Tesla, Buy This Magnificent Healthcare Stock Instead
↗
March 17, 2024
Vertex Pharmaceuticals already has a fantastic business, and it could get much bigger in the future.
Via
The Motley Fool
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
↗
March 09, 2024
Good news could be in store for all three of these drugmakers.
Via
The Motley Fool
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years
↗
March 08, 2024
Via
Benzinga
The Top 3 Biotech Stocks to Buy in March 2024
↗
March 06, 2024
Although the biotech sector puts the benefits and risks in plain sight, three top biotech stocks to buy shine for investors.
Via
InvestorPlace
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
↗
March 05, 2024
All three have exciting programs on the way.
Via
The Motley Fool
Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making
↗
March 05, 2024
These three companies represent the world of biotech stocks and offer a unique blend of high risk and potentially high reward.
Via
InvestorPlace
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
↗
March 04, 2024
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.
Via
InvestorPlace
ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential
↗
March 04, 2024
Here are three ChatGPT stock predictions for the most unpredictable of biotech stocks that might just have 10x potential.
Via
InvestorPlace
Topics
Artificial Intelligence
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
76
77
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.